The Indivior PLC (INDV) Earns Buy Rating from Numis Securities Ltd

The Indivior PLC (INDV) Earns Buy Rating from Numis Securities Ltd

INDV has been the subject of several other research reports. Deutsche Bank AG reissued a buy rating and issued a GBX 395 ($5.07) price objective on shares of Indivior PLC in a research report on Friday, February 3rd. Citigroup Inc increased their price objective on shares of Indivior PLC from GBX 320 ($4.11) to GBX 340 ($4.37) and gave the stock a neutral rating in a research report on Thursday, March 2nd. Stifel Nicolaus reissued a buy rating and issued a GBX 500 ($6.42) price objective on shares of Indivior PLC in a research report on Friday, February 3rd. Royal Bank of Canada lowered shares of Indivior PLC to a sector performer rating and increased their price objective for the stock from GBX 370 ($4.75) to GBX 390 ($5.01) in a research report on Monday, March 13th. Finally, Jefferies Group LLC increased their price objective on shares of Indivior PLC from GBX 440 ($5.65) to GBX 490 ($6.29) and gave the stock a buy rating in a research report on Monday, February 27th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Indivior PLC currently has a consensus rating of Buy and a consensus target price of GBX 419.29 ($5.39).

Numis Securities Ltd reissued their buy rating on shares of Indivior PLC (LON:INDV) in a report published on Wednesday. Numis Securities Ltd currently has a GBX 490 ($6.29) price target on the specialty pharmaceutical company’s stock.

Indivior PLC (LON INDV) opened at 329.70 on Wednesday. The firm has a 50-day moving average of GBX 325.82 and a 200 day moving average of GBX 322.37. Indivior PLC has a 12 month low of GBX 169.90 and a 12 month high of GBX 382.30. The stock’s market cap is GBX 2.38 billion. About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:INDV”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment